GlassScriptPhysician profile
Alyssa M Aragosa
NPI 1982063434
$2,784.91
in general payments reported to CMS, 2019-2025
31 companies · $701 in 2025
The $701 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $463 · 2022: $520 · 2023: $770 · 2024: $331 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,542 · Education: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,541.62 |
| Education | $260.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $314.47 | 2021-2023 | Kyprolis, Blincyto |
| Merck Sharp & Dohme LLC | $230.63 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $179.51 | 2022-2025 | |
| Beigene USA, INC. | $152.20 | 2022-2024 | Brukinsa |
| Seagen INC. | $143.18 | 2023-2025 | Adcetris |
| Regeneron Healthcare Solutions, INC. | $141.39 | 2022-2024 | Libtayo |
| Celgene Corporation | $137.67 | 2022-2024 | Reblozyl, Pomalyst, Opdualag |
| Aveo Pharmaceuticals, INC. | $134.19 | 2025 | |
| Smith+Nephew, INC. | $133.42 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $132.30 | 2022-2025 | Opdualag, Opdivo |
| Janssen Biotech, INC. | $114.51 | 2023-2025 | Rybrevant, Darzalex, Imbruvica |
| Lilly USA, LLC | $111.71 | 2022-2025 | Jaypirca, Verzenio |
| Genentech USA, INC. | $109.25 | 2022-2025 | Perjeta, Phesgo, Polivy |
| Daiichi Sankyo INC. | $108.04 | 2023-2025 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $89.49 | 2023-2025 | Enhertu, Calquence, Imfinzi |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $51.28 | 2024-2025 | Padcev, Xtandi |
| Coloplast Corp | $50.98 | 2021 | |
| Abbvie INC. | $48.63 | 2023 | |
| Adaptive Biotechnologies Corporation | $47.67 | 2024-2025 | Clonoseq |
| Novartis Pharmaceuticals Corporation | $46.39 | 2025 | |
| Incyte Corporation | $43.05 | 2023-2025 | Jakafi |
| Sobi, INC | $35.60 | 2022-2024 | |
| Eisai INC. | $31.46 | 2023 | |
| Gilead Sciences, INC. | $29.98 | 2023 | Trodelvy |
| Jazz Pharmaceuticals INC. | $28.90 | 2023 | |
| Puma Biotechnology, INC. | $26.50 | 2025 | |
| Alnylam Pharmaceuticals INC. | $26.02 | 2023 | Givlaari |
| Karyopharm Therapeutics INC. | $26.00 | 2025 | Xpovio |
| Tactile Systems Technology INC | $23.59 | 2023 | Flexitouch Plus, Entre Plus |
| Tersera Therapeutics LLC | $20.19 | 2024 | Xermelo |
| Emd Serono, INC. | $16.71 | 2023 | Bavencio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Aragosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.